Literature DB >> 24754307

Transient depletion of specific immune cell populations to improve adenovirus-mediated transgene expression in the liver.

Pilar Alzuguren1, Sandra Hervas-Stubbs, Gloria Gonzalez-Aseguinolaza, Joanna Poutou, Puri Fortes, Uxua Mancheno, Maria Bunuales, Cristina Olagüe, Nerea Razquin, Nico Van Rooijen, Monica Enguita, Ruben Hernandez-Alcoceba.   

Abstract

BACKGROUND & AIMS: Adenoviral (Ad) vectors are currently one of the most efficient tools for in vivo gene transfer to the liver. However, anti-Ad immune responses limit the safety and efficacy of these vectors. The initial inflammatory reaction is a concern in terms of toxicity, and it favours the development of cellular and humoral responses leading to short transgene persistence and inefficient vector re-administrations. Therefore, safe and simple ways to interfere with these processes are needed. Study ways to deplete specific immune cell populations and their impact on liver-directed gene transfer.
METHODS: First-generation Ad vectors encoding reporter genes (luciferase or β-galactosidase) were injected intravenously into Balb/c mice. Kupffer cells and splenic macrophages were depleted by intravenous administration of clodronate liposomes. B lymphocytes, CD4(+) , CD8(+) T lymphocytes or NK cells were depleted by intraperitoneal injection of anti-M plus anti-D, anti-CD4, anti-CD8 or anti-asialo-GM1 antibodies respectively. Long-term evolution of luciferase expression in the liver was monitored by bioluminescence imaging.
RESULTS: The anti-CD4 monoclonal antibody impaired cellular and humoral immune responses, leading to efficient vector re-administration. Clodronate liposomes had no impact on humoral responses but caused a 100-1000 fold increase in liver transduction, stabilized transgene expression, reduced the concentration of inflammatory cytokines, and inhibited lymphocyte activation.
CONCLUSIONS: Transient CD4(+) T-cell depletion using antibodies is a clinically feasible procedure that allows efficient Ad redosing. Systemic administration of clodronate liposomes may further increase the safety and efficacy of vectors.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  B cells; CD4+ T cells; CD8+ T cells; Kupffer cells; NK cells; adenovirus; clodronate liposomes; immunosuppression; monoclonal antibodies; neutralizing antibodies

Mesh:

Substances:

Year:  2014        PMID: 24754307     DOI: 10.1111/liv.12571

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  7 in total

1.  Safety and antitumor effect of oncolytic and helper-dependent adenoviruses expressing interleukin-12 variants in a hamster pancreatic cancer model.

Authors:  J Poutou; M Bunuales; M Gonzalez-Aparicio; E Garcia-Aragoncillo; J I Quetglas; R Casado; C Bravo-Perez; P Alzuguren; R Hernandez-Alcoceba
Journal:  Gene Ther       Date:  2015-05-04       Impact factor: 5.250

2.  Pathology in Permissive Syrian Hamsters after Infection with Species C Human Adenovirus (HAdV-C) Is the Result of Virus Replication: HAdV-C6 Replicates More and Causes More Pathology than HAdV-C5.

Authors:  Ann E Tollefson; Baoling Ying; Jacqueline F Spencer; John E Sagartz; William S M Wold; Karoly Toth
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

3.  Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.

Authors:  Tuuli Ranki; Sari Pesonen; Akseli Hemminki; Kaarina Partanen; Kalevi Kairemo; Tuomo Alanko; Johan Lundin; Nina Linder; Riku Turkki; Ari Ristimäki; Elke Jäger; Julia Karbach; Claudia Wahle; Matti Kankainen; Charlotta Backman; Mikael von Euler; Elina Haavisto; Tiina Hakonen; Raita Heiskanen; Magnus Jaderberg; Juuso Juhila; Petri Priha; Laura Suoranta; Lotta Vassilev; Antti Vuolanto; Timo Joensuu
Journal:  J Immunother Cancer       Date:  2016-03-15       Impact factor: 13.751

4.  Immunomodulatory Properties of Carvone Inhalation and Its Effects on Contextual Fear Memory in Mice.

Authors:  Aritz Lasarte-Cia; Teresa Lozano; Marta Pérez-González; Marta Gorraiz; Kristina Iribarren; Sandra Hervás-Stubbs; Pablo Sarobe; Obdulia Rabal; Mar Cuadrado-Tejedor; Ana García-Osta; Noelia Casares; Juan José Lasarte
Journal:  Front Immunol       Date:  2018-01-25       Impact factor: 7.561

5.  Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus.

Authors:  Sam Illingworth; Ying Di; Maxine Bauzon; Janet Lei; Margaret R Duffy; Simon Alvis; Brian Champion; André Lieber; Terry Hermiston; Len W Seymour; John Beadle; Kerry Fisher
Journal:  Mol Ther Oncolytics       Date:  2017-03-29       Impact factor: 7.200

Review 6.  High-Capacity Adenoviral Vectors: Expanding the Scope of Gene Therapy.

Authors:  Ana Ricobaraza; Manuela Gonzalez-Aparicio; Lucia Mora-Jimenez; Sara Lumbreras; Ruben Hernandez-Alcoceba
Journal:  Int J Mol Sci       Date:  2020-05-21       Impact factor: 5.923

7.  Macrophage Depletion via Clodronate Pretreatment Reduces Transgene Expression from AAV Vectors In Vivo.

Authors:  Darrick L Yu; Natalie S M Chow; Byram W Bridle; Sarah K Wootton
Journal:  Viruses       Date:  2021-10-06       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.